Target Name: Synuclein
NCBI ID: P48069
Other Name(s): None

Synuclein: A Protein Linked To Alzheimer's and Other Neurological Disorders

Synuclein is a protein that is found in the brain and has been linked to a number of neurological conditions, including Alzheimer's disease. It is also known as beta-amyloid protein 2 (BAPP2), and is thought to contribute to the development and progression of these conditions.

Recent studies have suggested that Synuclein may be a drug target or biomarker for the treatment of Alzheimer's disease and other neurological conditions. This is because it is thought to be involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease, and may also be involved in the destruction of healthy brain cells.

One way that Synuclein may be used to treat Alzheimer's disease is by targeting its role in the formation of beta-amyloid plaques. There is evidence that treatments that target beta-amyloid plaques, such as those used to treat Alzheimer's disease, may also be effective in reducing the amount of Synuclein available in the brain.

Another potential use for Synuclein as a drug target is its role in the destruction of healthy brain cells. This is thought to be a contributing factor to the development of Alzheimer's disease, and may also be involved in the progression of other neurological conditions. Targeting Synuclein with drugs that can preserve healthy brain cells may therefore be a promising approach to treating these conditions.

In addition to its potential as a drug target, Synuclein is also being studied as a biomarker for the diagnosis and progression of Alzheimer's disease. This is because its levels are often reduced in people with Alzheimer's disease, and its levels can be used as a marker for the disease.

Overall, Synuclein is a protein that is thought to be involved in a number of neurological conditions, including Alzheimer's disease. Its levels are often reduced in people with these conditions, and it may be a promising target for the development of new treatments. Further research is needed to fully understand its role and potential as a drug and biomarker.

Protein Name: Synuclein

More Common Targets

SYP | SYPL1 | SYPL2 | SYS1 | SYS1-DBNDD2 | SYT1 | SYT10 | SYT11 | SYT12 | SYT13 | SYT14 | SYT15 | SYT15B | SYT16 | SYT17 | SYT2 | SYT3 | SYT4 | SYT5 | SYT6 | SYT7 | SYT8 | SYT9 | SYTL1 | SYTL2 | SYTL3 | SYTL4 | SYTL5 | SYVN1 | SZRD1 | SZRD1P1 | SZT2 | T-Box transcription factor (TBX) | T-Type Calcium Channel | TAAR1 | TAAR2 | TAAR3P | TAAR5 | TAAR6 | TAAR8 | TAAR9 | TAB1 | TAB2 | TAB2-AS1 | TAB3 | TAC1 | TAC3 | TAC4 | TACC1 | TACC2 | TACC3 | Tachykinin Receptor | TACO1 | TACR1 | TACR2 | TACR3 | TACSTD2 | TADA1 | TADA2A | TADA2B | TADA3 | TAF1 | TAF10 | TAF11 | TAF11L2 | TAF11L3 | TAF12 | TAF12-DT | TAF13 | TAF15 | TAF1A | TAF1A-AS1 | TAF1B | TAF1C | TAF1D | TAF1L | TAF2 | TAF3 | TAF4 | TAF4B | TAF5 | TAF5L | TAF5LP1 | TAF6 | TAF6L | TAF7 | TAF7L | TAF8 | TAF9 | TAF9B | TAFA1 | TAFA2 | TAFA3 | TAFA4 | TAFA5 | TAFAZZIN | TAGAP | TAGAP-AS1 | TAGLN | TAGLN2